# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-24-071756
Filing Date
2024-06-14
Accepted
2024-06-14 16:10:50
Documents
6
Period of Report
2024-08-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRE 14A | tm2417053-1_pre14a.htm | PRE 14A | 811515
2 | GRAPHIC | bc_companytsr-4c.jpg | GRAPHIC | 52940
3 | GRAPHIC | bc_netincome-4c.jpg | GRAPHIC | 50588
4 | GRAPHIC | lg_outlooktherapeutics-4clr.jpg | GRAPHIC | 18748
5 | GRAPHIC | px_24outlookproxy1pg01-bw.jpg | GRAPHIC | 301630
6 | GRAPHIC | px_24outlookproxy1pg02-bw.jpg | GRAPHIC | 268795
| Complete submission text file | 0001104659-24-071756.txt |  | 1712055

Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: PRE 14A | Act: 34 | File No.: 001-37759 | Film No.: 241044857
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)